These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

987 related items for PubMed ID: 19291793

  • 1. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.
    Int J Cancer; 2009 Jul 01; 125(1):71-7. PubMed ID: 19291793
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H.
    Cancer Res; 2009 Dec 15; 69(24):9337-45. PubMed ID: 19934315
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

  • 4. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS, Kim MJ, Bae JH, Song HS, Chung BS, Lee MK, Kang CD, Lee HS, Kim DW, Kim SH.
    Cancer Lett; 2007 Jul 08; 252(1):75-85. PubMed ID: 17223257
    [Abstract] [Full Text] [Related]

  • 5. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA, Jusoh SA, Yong AC, Asan JM, Hassan R, Johan MF.
    Asian Pac J Cancer Prev; 2014 Jul 08; 15(11):4555-61. PubMed ID: 24969884
    [Abstract] [Full Text] [Related]

  • 6. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
    Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.
    PLoS One; 2013 Jul 08; 8(4):e61939. PubMed ID: 23613979
    [Abstract] [Full Text] [Related]

  • 7. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
    Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O.
    Apoptosis; 2010 May 08; 15(5):608-20. PubMed ID: 20094798
    [Abstract] [Full Text] [Related]

  • 8. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
    Dong Y, Xiong M, Duan L, Liu Z, Niu T, Luo Y, Wu X, Xu C, Lu C.
    Apoptosis; 2014 Aug 08; 19(8):1281-92. PubMed ID: 24830786
    [Abstract] [Full Text] [Related]

  • 9. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
    Blood; 2004 Oct 15; 104(8):2532-9. PubMed ID: 15256422
    [Abstract] [Full Text] [Related]

  • 11. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, Broxmeyer HE, Ohyashiki JH, Ohyashiki K.
    Stem Cells Dev; 2007 Jun 15; 16(3):503-14. PubMed ID: 17610380
    [Abstract] [Full Text] [Related]

  • 12. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 13. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.
    Cancer Res; 2005 Oct 15; 65(20):9436-44. PubMed ID: 16230407
    [Abstract] [Full Text] [Related]

  • 14. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T.
    Leukemia; 2003 Jun 15; 17(6):999-1009. PubMed ID: 12764361
    [Abstract] [Full Text] [Related]

  • 15. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM.
    Blood; 2012 Mar 08; 119(10):2335-45. PubMed ID: 22262776
    [Abstract] [Full Text] [Related]

  • 16. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
    Ma D, Fang Q, Wang P, Gao R, Wu W, Lu T, Cao L, Hu X, Wang J.
    J Biol Chem; 2015 May 15; 290(20):12558-71. PubMed ID: 25802333
    [Abstract] [Full Text] [Related]

  • 17. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
    Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, Konopleva M, Andreeff M, Radomski MW, Ruvolo PP.
    Cell Cycle; 2008 Nov 01; 7(21):3362-70. PubMed ID: 18948750
    [Abstract] [Full Text] [Related]

  • 18. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y, Nakamura S, Okinaka K, Hirano I, Ono T, Shigeno K, Shinjo K, Ohnishi K.
    Leuk Res; 2008 Jun 01; 32(6):962-71. PubMed ID: 18190961
    [Abstract] [Full Text] [Related]

  • 19. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 01; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

  • 20. Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage.
    Goldberg Z, Levav Y, Krichevsky S, Fibach E, Haupt Y.
    Cell Cycle; 2004 Sep 01; 3(9):1188-95. PubMed ID: 15467443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.